He added that these findings “support ribociclib and nonsteroidal aromatase inhibitors as a new treatment of choice in a broad population – broader than we’ve seen before – of patients with stage II and stage III disease.”

The addition of the AKT inhibitor capivasertib to fulvestrant significantly prolongs the progression-free survival of people with hormone receptor-positive, HER2-negative advanced breast cancer that is resistant aromatase inhibitors, indicate the results of CAPItello-291.

Participants either did or did not receive abemaciclib 150 mg twice daily for up to 2 years alongside standard of care ET with an aromatase inhibitor or tamoxifen.

The double-blind trial included 131 women (median age 54.9 years) who were on a stable dose of adjuvant tamoxifen or an aromatase inhibitor and reported at least 50 moderate to severe vasomotor symptoms – hot flashes or night sweats – per week.

Extending adjuvant aromatase inhibition to beyond 5 years of sequential therapy should not be recommended to all postmenopausal women with hormone receptor-positive early breast cancer, but some subgroups may benefit, research suggests.

Updated findings from the MONARCH 3 trial show a nonsignificant overall survival gain with the addition of abemaciclib to a first-line nonsteroidal aromatase inhibitor in postmenopausal patients with hormone receptor-positive, HER2-negative advanced breast cancer.

Concurrent use of tamoxifen with a direct oral anticoagulant is not associated with an increased risk for major hemorrhage compared with concurrent use of aromatase inhibitors in people with breast cancer, research suggests.

Dalpiciclib given in combination with an aromatase inhibitor offers a novel first-line treatment option for patients with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer, say the DAWNA-2 investigators.

However, the team identified a small but significant increased risk for recurrent breast cancer among the subgroup of VET users who were taking adjuvant aromatase inhibitors (AIs), albeit without an accompanying increased risk for mortality.

Analysis showed that patients given aromatase inhibitors were significantly more likely to respond than those given tamoxifen (78.1 vs 41.1%), and that ET response was significantly more common in patients with an RS 0–11 than their counterparts with an RS of 12–25 or greater than 25 (78.8 vs 62.2 and 32.7%, respectively).

Aromatase inhibitors significantly reduce the risk for breast cancer recurrence relative to tamoxifen in premenopausal women treated with ovarian function suppression, suggests a patient-level meta-analysis.

The CHMP decision also states that pre- or perimenopausal women receiving aromatase inhibitor endocrine therapy should additionally receive concurrent treatment with a luteinizing hormone-releasing hormone agonist.

Women with hormone receptor-positive, HER2-negative metastatic breast cancer benefit from switching from an aromatase inhibitor to fulvestrant in palbociclib combination therapy when an ESR1 mutation is detected without disease progression, phase 3 PADA-1 trial data show.

They also suggest that assessing nonpathologic fracture risk by different treatment types, such as receipt of aromatase inhibitors or chemotherapy, might help identify women who will benefit from “aggressive” treatment to reduce the risk of osteoporotic fractures. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group JAMA Netw Open 2021; doi:10.1001/jamanetworkopen.2021.33861

Extending adjuvant aromatase inhibitor therapy with letrozole to 5 years improves survival among women with hormone receptor-positive breast cancer who have already received 2 to 3 years of tamoxifen, shows the phase 3 GIM4 trial.

As per the prescribing information , abemaciclib should be given at a starting dose of 150 mg twice daily in combination with tamoxifen or an aromatase inhibitor for up to 2 years. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group

The phase 2 study included 199 patients with resistance to selective estrogen receptor modulators who were randomly assigned to receive the mTOR inhibitor everolimus at a dose of 10 mg daily plus the aromatase inhibitor letrozole 2.5 mg daily (n=101) or letrozole monotherapy at the same dose (n=98).

The phase 3 study was initiated following preclinical work indicating that resistance to aromatase inhibitors such as letrozole “can be reversed” by intermittent use, explain the researchers, who recruited 4851 postmenopausal patients with node-positive disease who had already received 4–6 years of adjuvant endocrine therapy.

The phase 3 SALSA trial has demonstrated no benefit of extending aromatase inhibitor therapy by 5 years versus 2 years in postmenopausal women with hormone receptor-positive breast cancer who have already received 5 years of adjuvant endocrine therapy.

The addition of a gonadotropin-releasing hormone analog to tamoxifen or an aromatase inhibitor decreases estradiol levels of men with HR-positive breast cancer, phase 2 trial data show.